Text ::   Skip Nav ::

circare logo


Brochure Contact Home Privacy Site Map Terms of Use Tools

print Print Page ::   Link to CIRCARE Link To ::

Medical Board Orders for Physicians Associated with the Great Lakes College of Clinical Medicine

Josephine Clara Aronica, M.D. State Medical Board of Ohio Citation and Notice of Opportunty for Hearing. 2009-02-19: http://www.circare.org/pd/aronica_20090219.pdf (20)

Robert Mcree Battle M.D.   Dr. Battle is a longtime member of the Great Lakes Association of Clinical Medicine, and is currently a member of the board of directors of the International College of Integrative Medicine, formerly known as the Great Lakes Association of Clinical Medicine. (1)

Before the Texas State Board of Medical Examiners In the Matter of the Complaint Against Robert Mcree Battle M.D. Complaint. 2002-07-12. NB: this complaint was dismissed on 2002-10-18. Available from http://www.circare.org/pd/battletxcomplaint_20020712.pdf

Before the Texas State Board of Medical Examiners In the Matter of the Complaint Against Robert Mcree Battle M.D. Agreed Order. 1990-02-16. Available from http://www.circare.org/pd/battletxorder_19900216.pdf

Daniel J. Clark M.D.   Dr. Clark's license was revoked for experimentation without obtaining adequate informed consent, making deceptive, untrue, or fraudulent representations etc., while providing experimental cancer treatment that led to the death of one person. Dr. Clark is currently a board advisor to the International College of Integrative Medicine, formerly known as the Great Lakes Association of Clinical Medicine. (2)

State of Florida Board of Medical Examiners, Department of Health vs. Daniel J. Clark M.D. Recommended Order. 1983-09-13. Available from http://www.doah.state.fl.us/ros/1982/82%2D1220%2EPDF

William J. Faber D.O.   Dr. Faber was a member of the Great Lakes College of Clinical Medicine Institutional Review Board. (3)

State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against William J. Faber D.O. Case no. LS0211222MED. Amended Final Decision and Order. 2003-12-23. Available from http://drl.wi.gov/dept/decisions/docs/0104019.htm

Timoteo L. Galvez M.D.   Dr. Galvez was a member of the Great Lakes College of Clinical Medicine as of 1999. (4)

State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against Timoteo L. Galvez M.D. Case no. 89MED203. Final Decision and Order. 1992-10-23. Available from http://drl.wi.gov/dept/decisions/docs/DE00000000456-19921216.pdf

Eleazar Mira Kadile M.D.   Dr. Kadile is member of the International College of Integrative Medicine, formerly known as the Great Lakes Association of Clinical Medicine. (5)

State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against Eleazar Mira Kadile M.D. Complaint. 2001-12-03. Available from http://quackwatch.org/11Ind/kadile.html

State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against Eleazar Mira Kadile M.D. Final Decision and Order. 2003-11-21. Available from http://drl.wi.gov/dept/decisions/docs/1103014.htm

State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against Eleazar Mira Kadile M.D. Required Disclosure for Ethylenediaminetetraacetic Acid (EDTA) Chelation Therapy. 2003-11-21. Available from http://quackwatch.org/11Ind/kadile3.html

Roy Eugene Kerry M.D.   Dr. Kerry was a member of the Great Lakes College of Clinical Medicine as of 1999. (6)

Commonwealth of Pennsylvania Department of State Before the State Board of Medicine. Order to Show Cause. 2006-09-08. Available from http://www.circare.org/pd/kerry_ordertoshowcause_20060908.pdf

top

Warren Levin M.D.   The Connecticut board alleged, among other things, that Dr. Levin used Dimercapto-propane sulfonate (DMPS) and PolyMVA (drugs without FDA marketing approvals). According the Investigative Report The consultant states that the documentation respondent provided regarding his involvement in research is unacceptable. Respondent's billing records suggest another motive for performing the tests. The material provided to support some of respondent's practices and tests, includes case series, testimonials and commentary. There is no evidence of randomized, blinded, or reproducible research. The research documentation respondent provided does not include the protocol used, informed consent, quality controls, signed statement of the investigator, the Institutional Review Board or the FDA's IND document. The consultant questions why were the patients involved in research required to pay for their tests and treatments. On 2005-06-05 Dr. Levin signed a consent agreement which restricted re-application for licensure in Connecticut but specifically denied any and all wrong-doing. Dr. Levin was the principal investigator for a study titled Effects of Growth Hormone (GH) or Growth Hormone Releasing Hormone (GRF) on Age-Related Insulin Resistance, Pulmonary Function and Quality of Life which was reviewed and approved by the Great Lakes College of Clinical Medicine Institutional Review Board. (7)

State of Connecticut Department of Health Services, Connecticut Board of Medical Examiners. In re: Warren Levin M.D. Consent Order. 2005-06-05. Available from http://www.bioethicswatch.org/pd/levin_20030114001005.pdf

State of Connecticut Department of Health Services, Connecticut Board of Medical Examiners. In re: Warren Levin M.D. Investigative Report. 2003-12-16. Casewatch.org web site. Available from http://www.casewatch.org/board/med/levin/inv.shtml

William J. Mauer, Jr., D.O. The Florida Board of Osteopathic Medicine revoked Dr. Mauer's license following disciplinary actions by the Illinois Department of Professional Regulation for failure to file and pay Illinois state income taxes (2000) and for preying upon vulnerable and desperate people seeking help for ailments, lack of insight into proper diagnosis and patient care, and concern over Respondent's ethics (1998). Dr. Mauer was the principal investigator for a study titled Phototherapy as a Modality in the Stimulation of the Immune System which was reviewed and approved by the Great Lakes College of Clinical Medicine Institutional Review Board. (18)

State of Florida Board of Osteopathic Medicine, William J. Mauer, Jr., D.O. Final Order. 2002-10-09: http://www.circare.org/pd/mauer_fl20021009.pdf

Leonard Maitland McEwen BM BCh   Dr. McEwan provided investigational biologic products for research testing Enzyme Potentiated Desensitization (EPD), which was reviewed and approved by the Great Lakes College of Clinical Medicine IRB and conducted over several years by Welman A. Shrader, M.D. and more than seventy co-investigators. On 2001-04-04 FDA sent a warning letter to principal investigator Shrader objecting to various violations of FDA regulation including failure to obtain informed consent and failure to file an Investigational New Drug application prior to enrolling research subjects. (8) On 2006-09-01 the General Medical Council found Dr. McEwan's fitness to practice to be impaired as a result of failure to maintain patient confidentiality and improbity in soliciting patients to invest in the manufacture of components of EPD, in which latter Dr. McEwan had a significant financial stake. Among other things, the council determined that:

The Panel has heard that you have worked for a number of years as a private practitioner offering medical advice and treatment for allergies and food intolerances. During the course of your work you saw patients and provided them with Enzyme Potentiated Desensitisation (EPD) treatment, which was manufactured by a small family company, McEwen Laboratories Ltd. The Panel has heard that you were the Scientific Director of, and a shareholder of, McEwen Laboratories Ltd, owning 34% of the company. You were one of four Directors of the company, the others being your wife and two of your sons.

The EPD Study Office of McEwen Laboratories maintained a database of patients in order to assist in the evaluation of the efficacy of EPD treatment. The information held on this database was drawn from treatment evaluation forms completed by patients who had received EPD treatment. This included forms from patients who had received EPD treatment from you. You were responsible for obtaining this information and the use of the information supplied for clinical purposes.

In 2004 a group of patients who had commenced EPD treatment received a letter. You were the first signatory of this letter in your capacity as a doctor. The letter indicated that in order to secure the future of EPD treatment, McEwen Laboratories Ltd needed to take steps towards the full licensing and marketing of the product, intended to raise capital through a new company, Epidyme Ltd, and that Epidyme Ltd needed to raise approximately 300,000 in order to commence operations. The letter stated that the minimum level of investment was 5,000 and that the capital raised was intended to begin the process of exploiting on a commercial scale the intellectual property of McEwen Laboratories Ltd.

A decision was taken in June 2004 by the Directors of McEwen Laboratories Ltd, at a Board meeting, to use information held on the database as the source material for the letter soliciting funding. You were present at the meeting in your capacity as Chairman/Managing Director and Scientific Director of McEwen Laboratories Ltd. You acquiesced to the use of the information held on the database and therefore permitted McEwen Laboratories Ltd to use the names and contact details of the patients, all of whom had received EPD treatment.

The EPD patients were informed in the letter that we are writing to you because we believe that you have received one or more shots of EPD and that we hope you have benefited from EPD and would like the treatment to remain available. The letter concluded with the sentence that we know that without this capital the production of EPD will not be able to continue. You thereby encouraged patients to invest in Epidyme Ltd, in which McEwen Laboratories Ltd would be the majority shareholder, by implying that, without such investment, their treatment would no longer be available.

The Panel has found that by your actions you have breached the confidence of patients and that your actions were inappropriate and unprofessional.

General Medical Council. Fitness to Practise Panel decision of 2006-09-01. Available from http://www.gmc-uk.org/concerns/decisions/search_database/ftp_panel_mcewen_20060829.asp

top

Kirk Morgan M.D.   Dr. Morgan was an original member of the Great Lakes College of Clinical Medical Institutional Review Board, ca. 1991. The Great Lakes College of Clinical Medicine Institutional Review Board is mentioned in the earliest stipulation. (9)

Order of Indefinite Restriction Commonwealth of Kentucky Board of Medical Licensure. Administrative Action No. 00-KBML-0132. In RE: The License to Practice Medicine in the Commonwealth of Kentucky Held by Kirk D. Morgan M.D. 2003-08-12. Available from http://www.state.ky.us/agencies/kbml/finalorders/16289.pdf

Roy C. Page, M.D. Before the Tennessee Board of Medical Examiners in the Matter of Roy C. Page, M.D. Amended Agreed Order. 2008-02-24: http://www.circare.org/pd/page_20080124.pdf

Theodore Carl Rozema M.D. Dr. Rozema was a member of the Great Lakes College of Clinical Medicine Institutional Review Board, former member of the board of directors of the Great Lakes Association of Clinical Medicine, and is currently a principal of the International College of Integrative Medicine, formerly known as the Great Lakes Association of Clinical Medicine. (10)

Before the Board of Medical Examiners of the State of North Carolina. In re: Theodore Carl Rozema M.D. Findings of Fact, Conclusions of Law and Order. Order. 1978-10-26. Available from http://www.bioethicswatch.org/pd/rozema_19781026.pdf

Before the Board of Medical Examiners of the State of North Carolina. In re: Theodore Carl Rozema M.D. Consent Order. 1990-01-29. Available from http://www.bioethicswatch.org/pd/rozema_19900129.pdf

Before the Board of Medical Examiners of the State of North Carolina In re: Theodore Carl Rozema M.D. Submission of Memorandum on Chelation Therapy. 1984-12-10. Available from http://www.bioethicswatch.org/pd/rozemamemorandum_19841210.pdf

James Michael Shortt M.D. Dr. Shortt was a member of the Great Lakes College of Clinical Medicine as of 1999. (11)

Before the South Carolina State Board of Medical Examiners in the Matter of James Michael Shortt. Order of Temporary Suspension. 2005-04-13. Available from http://www.llr.state.sc.us/pol/medical/Final%20Orders/shorttTSO.pdf

Before the South Carolina State Board of Medical Examiners in the Matter of James Michael Shortt. Final Order. 2006-05-28. Available from http://www.llr.state.sc.us/pol/medical/Final%20Orders/May06/ShorttFO.pdf

Related: SCDLLR vs. Anonymous Physician. Docket Number: 04-ALJ-11-0329-IJ. Order Denying Motion. 2004-11-18. State of South Carolina Administrative Law Court. Available from http://www.scaljd.net/decision.asp?id=1096

Related: SCDLLR vs. Anonymous Physician. Docket Number: 04-ALJ-11-0344-IJ. 2004-12-17. State of South Carolina Administrative Law Court. Available from http://www.scaljd.net/decision.asp?id=1175

Related: United States of America v. James M. Shortt. Superceding Indictment. 2005-11. United States District Court District of South Carolina Columbia Division. Available from http://www.casewatch.org/doj/shortt/indictment.shtml

Related: David W. Bibeau, Personal Representative of the Estate of Katherine Ann Kurtz-Bibeau, v. James Michael Shortt; Health Dimensions, LLC; and Congaree Pharmacy, Inc. Case No. 3 04 22306 10. Complaint. 2004-09-22. United States District Court District of South Carolina Columbia Division. Available from http://www.quackwatch.org/11Ind/shortt.html

Related: Janet H. Bate, as Personal Representative of the Estate of Michael Andrew Robertson Bate, v. James Michael Shortt. Case No. 3:06-cv-00647-MKP. Complaint. 2006-05-03. United States District Court District of South Carolina Columbia Division. Available from http://www.casewatch.org/mal/shortt/bate.shtml

top

Robban Sica M.D. On 2005-02-15 Dr. Sica signed a consent order with the Connecticut Board of Medical Examiners in which she agreed 1) not to use Dimercapto-propane sulfonate (DMPS) unless and until it was approved by the FDA, 2) not to own or have shares in any professional corporation or other form of medical practice in which she did not conduct a substantial practice of patient care, and 3) to comply with additional terms and conditions during a one year period of probation. On 2002-01-17 Dr. Sica signed a consent agreement with the New York State Board for Professional Medical Conduct in which she agreed not to renew her medical license in New York state and to dissolve or divest herself from interests in 32 medical professional service corporations. Dr. Sica is a member of the board of directors of The International College of Integrative Medicine Inc., formerly known as the Great Lakes Association of Clinical Medicine. (12)

State of Connecticut Department of Health Services, Connecticut Board of Medical Examiners. In re: Robban Sica M.D. Consent Order. 2005-02-15. Available from http://www.bioethicswatch.org/pd/sica_20020306001043.pdf

State of New York Department of Health State Board for Professional Medical Conduct. In the Matter of Robban Sica M.D. Consent Agreement and Order. 2002-01-17. Available from http://w3.health.state.ny.us/opmc/factions.nsf/58220a7f9eeaafab85256b180058c032/b64f4476587d526085256b49005ede45/$FILE/lc199255.pdf

Related: Madeline Parker vs. M. Wolinsky-Friedlan, M.D. and Robban Sica, M.D. Case No. CV-02-0470262-S. Superior Court of Connecticut. Judicial District of New Haven. Plaintiff alleges she was misled in research and harmed by the drug Dimercapto-propane sulfonate (DMPS). The case is pending.

Jack E. Slingluff D.O. Dr. Slingluff is a founding member of the Great Lakes Association of Clinical Medicine. (13) On 2004-03-16 Dr. Slingluff signed a plea agreement to settle federal charges arising from the sale of Laetrile to FDA undercover agents:

Osteopath Found Administering Intravenous Laetrile Treatments to Cancer Patients

This investigation was initiated in May 2002, based on a consumer complaint to FDA's Cincinnati District Office regarding Dr. Jack Edwin Slingluff, Canton, Ohio, a licensed osteopath. The complaint alleged that Dr. Slingluff was administering intravenous Laetrile treatments for cash to a cancer patient now deceased.

In August 2002, while at Lake Cable Medical Center, his medical practice in Canton, Ohio, Dr. Slingluff confirmed that he administered Laetrile treatments to his patients but required them to obtain their own Laetrile. FDA reviewed a paper entitled Laetrile Order Info which contained the name Betty Miller, a telephone number, and a company name of Healthy Options, and later a Laetrile package with a return address listing a post office box located in West Palm Beach, Florida.

In October 2002, U.S. Postal Service records were reviewed and it was determined that the post office box listed on the package was registered to Marilyn Norton in Florida.

On January 30, 2003, three federal search warrants were served for Dr. Slingluff's medical practice, Norton's business address, and Norton's residence. During the search at Norton's residence, she advised that she had been in business for approximately two years, that she was aware that Laetrile was used for the treatment of cancer and that she has been involved with Laetrile for approximately 30 years as her former husband, Steven Michaelis (deceased) also sold Laetrile. After the warrant, it was determined that Norton was the mother of Kenneth Michaelis who had been previously prosecuted. Kenneth Michaelis was convicted of two felony counts of distributing the unapproved new drugs Laetrile and Hydrazine Sulfate.

In March 2004, Dr. Slingluff was convicted of violating 21 U.S.C. §§ 331(d), 355(a) and 333(a)(1) - Interstate Distribution of an Unapproved New Drug. In May 2004, Dr. Slingluff was sentenced to serve 1 year supervised probation. In April 2005, Norton was convicted of violating 18 U.S.C. § 371 - Conspiracy; 21 U.S.C. §§ 331(p) and 333(a)(1) - Failure to Register a Drug Manufacturing Facility; and 21 U.S.C. §§ 331(a), 333(a)(1) and 352 - Introduction into Interstate Commerce of a Misbranded Drug. Norton was sentenced to serve 2 years supervised probation. (4)

The Ohio State Medical Board proposed to discipline Dr. Slingluff on the basis of the federal case. On 2004-12-13 Dr. Slingluff filed an appeal of the decision of the medical board in the Court of Common Pleas of Franklin County, Ohio. On 2005-08-04 the Court of Common Pleas of Franklin County upheld the decision of the medical board. Dr. Slingluff filed an appeal in the Court of Appeals of Ohio Tenth Appellate Division which likewise upheld the medical board in a decision handed down on 2006-07-11, whereupon he appealed this decision in the Supreme Court of Ohio. The court issued an entry order on 2006-12-13 in which it declined the hear the case. On 2008-12-10 Dr. Slingluff agreed to voluntarily surrender his medical license and consented to permanent revocation. (19)

Before the State Medical Board of Ohio In the Matter of Jack Edwin Slingluff, D.O. Entry of Final Order. 2008-12-10: http://www.circare.org/pd/slingluff_20081210.pdf

United States vs. Jack Edwin Slingluff D.O. Case No. 04CR074. Information. United States District Court for the Northern District of Ohio Eastern Division. 2004-02-11: http://www.bioethicswatch.org/pd/slingluff_information.pdf

United States vs. Jack Edwin Slingluff D.O. Case No. 04CR074. Plea Agreement. United States District Court for the Northern District of Ohio Eastern Division. 2004-03-16: http://www.bioethicswatch.org/pd/slingluff_pleaagreement.pdf

top

Stephen L. Smith M.D. Dr. Smith was a member of the Great Lakes College of Clinical Medicine as of 1999. (14)

State of Washington Department of Health Medical Quality Assurance Commission In the Matter of the License to Practice as a Physician and Surgeon of Stephen L. Smith, M.D. Findings of Fact, Conclusions of Law and Final Order. 2006-02-21. NB 2006-04-14: Final Order stayed pending appeal. Available from http://www.circare.org/pd/smithfinalorder_20060221.pdf

State of Washington Department of Health Medical Quality Assurance Commission In the Matter of the License to Practice as a Physician and Surgeon of Stephen L. Smith, M.D. Amended Statement of Charges. 2006-01-03. Available from http://www.circare.org/pd/smithamdsoc_20060103.pdf

State of Washington Department of Health Medical Quality Assurance Commission In the Matter of the License to Practice as a Physician and Surgeon of Stephen L. Smith, M.D. Statement of Charges. 2005-05-06. Available from http://www.circare.org/pd/smithsoc_20050506.pdf

Robert Snider M.D. The New York Board for Professional Medical Conduct restricted Dr. Snider's license and put him on probation for failure to meet acceptable standards of care in the case of seven patients. Among other things the board found that Dr. Snider fraudulently informed patients that DMPS may be prescribed by a physician under the Medical Practice Act of the United States, where there is no such act. Dr. Snider appears on a list of site investigators in research testing Dimercapto-propane sulfonate (DMPS) conducted by principal investigator Paula Bickle. The research was reviewed and approved by The Great Lakes College of Clinical Medicine Institutional Review Board. (16)

State of New York Department of Health State Board for Professional Medical Conduct. In the Matter of Robert Snider M.D. Consent Agreement and Order. 1999-01-12. Available from http://www.circare.org/pd/snidernyorder_19990112.pdf

John Parks Trowbridge M.D. Dr. Trowbridge was a member of the Great Lakes College of Clinical Medicine Institutional Review Board, former member of the board of directors of the Great Lakes Association of Clinical Medicine, and is currently a principal of the International College of Integrative Medicine, formerly known as the Great Lakes Association of Clinical Medicine. (17)

In the Matter of the License of John Parks Trowbridge M.D. Before the Texas State Board of Medical Examiners. Order. 1990-10-22. Available from http://www.bioethicswatch.org/pd/trowbridge_order19901022.pdf

In the Matter of the License of John Parks Trowbridge M.D. Before the Texas State Board of Medical Examiners. Agreed Order. 1998-08-22. Available from http://www.bioethicswatch.org/pd/trowbridge_order19980822.pdf

Richard L. Vander Heyden, DDS   According to the Final Decision and Order issued by the Wisconsin Dentistry Examining Board on 2005-07-13:

… Dr. Vander Heyden testified at a deposition held on April 23, 2004 that, starting around 1991 through the late 1990s, he was a member of the Great Lakes Association of Clinical Medicine, a professional organization of medical practitioners. While a member of the Association, Dr. Vander Heyden heard about a study that the Association was conducting relating to the use of an EAV (Electro-Acupuncture according to Voll) device. The study was referred to as the Colquitt-Regianni study. Dr. Vander Heyden inquired about the study and at some point in time agreed to participate in conducting the study. He purchased an EAV device for use in the study from Esion, a company located in Utah, for about $28,000. The device was called Interro (Intero). Hearing Exhibit 6, p. 9-14.

Dr. Vander Heyden testified that his role in the Interro project conducted by Colquitt and Regianni was to gather data for the research. He used information that he obtained from his treatment of several of his patients from his dental practice, including Patients KP and BD, to gather data for the study. He charged his patients between $100 and $225 for the time that he spent doing the research. He compared the patients' response on the EAV testing to the results from the Clifford materials reactivity testing. He kept records of the testing and comparison and, at some point in time, turned the patients' records of the EAV results over to Great Lakes.

State of Wisconsin Before the Dentistry Examining Board in the Matter of the Disciplinary Proceedings Against Richard L. Vander Heyden DDS. Case No. LS0312302DEN. Final Decision and Order. 2005-07-13. Available from http://drl.wi.gov/dept/decisions/docs/20050713VanderHeyden.htm


Notes

1. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm. International College of Integrative Medicine, Board Members. International College of Integrative Medicine web site. Accessed on 2006-11-02 at: http://icimed.com/board2007.php

2. International College of Integrative Medicine, Board Advisors. International College of Integrative Medicine web site. Accessed on 2006-11-02 at: http://icimed.com/board2007.php

3. IRB member: Chappell, LT. Letter in reply to FDA warning letter. 2000-03-17. Available from http://www.circare.org/foia2/glccm_fda20000317.pdf. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

4. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

5. International College of Integrative Medicine Member Directory. Accessed on 2007-04-07 at: http://icimed.com/member_display_individual_v2.php?id=93

6. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

7. IRB approval: List of studies approved by the GLCCM IRB and enrolling subjects in March, 2000 when FDA suspended the IRB's authority. Available from http://www.circare.org/foia2/glccmstudies.pdf. See also: Minutes of the Great Lakes College of Clinical Medicine Institutional Review Board, IRB meeting of 2000-02-25. Available from http://www.circare.org/foia2/glccm_irbmin20000225.pdf. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

8. See for example the Consent Form for Enzyme Potentiated Desensitization (EPD), p. 2: http://www.circare.org/foia2/epd_consentforms1998.pdf. See also: Masiello SA. FDA Warning Letter to Welman A. Shrader Jr., M.D. 2001-04-04: http://www.fda.gov/foi/warning_letters/archive/g1069d.pdf. Site Investigators List for Enzyme Potentiated Desensitization (EPD) study: http://www.circare.org/foia2/epd_siteinvestigators.pdf

9. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm; Member of the GLCCM IRB: Chappell LT. Letter of approval by the Great Lakes Association of Clinical Medicine Institutional Review Board to H. Heimlich M.D. for Induced Malaria study. 1994-05-27. Available from http://www.circare.org/foia2/glccm_hh19940527.pdf

10. IRB member: Chappell, LT. Letter in reply to FDA warning letter. 2000-03-17. Available from http://www.circare.org/foia2/glccm_fda20000317.pdf. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm. International College of Integrative Medicine, Executive Board. International College of Integrative Medicine web site. Accessed on 2006-11-02 at: http://icimed.com/board2007.php

11. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

12. International College of Integrative Medicine, Board Members. International College of Integrative Medicine web site. Accessed on 2006-11-02 at: http://icimed.com/board2007.php

13. Great Lakes Association of Clinical Medicine, Articles of Incorporation. 1983-09-06. Ohio Secretary of State corporation database. Accessed on 2006-11-02 at: http://www1.sos.state.oh.us/reports/rwservlet?imgc&Din=F323_0692. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

14. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-12-07 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

15. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-12-07 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

16. Referral Listing, New York. Cascade Health Group. 1998-12-05. Available from http://web.archive.org/web/19981205184244/www.cascade-web.com/referral.html. Approval by the Great Lakes College of Clinical Medicine Institutional Review Board: 1) IRB Multi-center Approved Active Project List. Paula Bickle Ph.D., The Effects of DMPS in a Total Mercury Detoxification Protocol (Study # M013). 2000. Available from http://www.circare.org/foia2/glccmstudies.pdf; 2) Great Lakes Association of Clinical Medicine. Mercury and DMPS Usage. Great Lakes Association of Clinical Medicine web site. 1999-03-20. Accessed on 2006-01-31 at: http://web.archive.org/web/19990302080253/www.arxc.com/glacm/dmps.htm. Great Lakes Association of Clinical Medicine, List of Members (1999-02-18). Great Lakes Association of Clinical Medicine web site. Accessed on 2006-11-02 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm

17. IRB member: Chappell, LT. Letter in reply to FDA warning letter. 2000-03-17. Available from http://www.circare.org/foia2/glccm_fda20000317.pdf. International College of Integrative Medicine, Executive Board. International College of Integrative Medicine web site. Accessed on 2006-11-02 at: http://icimed.com/board2007.php

18. List of studies approved by the GLCCM IRB and enrolling subjects in March, 2000 when FDA suspended the IRB's authority. Available from http://www.circare.org/foia2/glccmstudies.pdf

19. Jack Edward Slingluff, D.O., Ohio Licensee Profile and Status. Accessed on 2007-02-19 at: https://license.ohio.gov/Lookup/SearchDetail.asp?ContactIdnt=2996833&DivisionIdnt=78&Type=L

20. GLCCM member 1999. Great Lakes College of Clinical Medicine Members. Accessed on 2009-04-09 at: http://web.archive.org/web/19990218132130/www.arxc.com/glacm/members.htm


top

If you find the information on this page helpful please support CIRCARE with a tax-deductible contribution today. Because CIRCARE doesn't accept funds from pharmaceutical or medical device manufacturers, we depend on contributions from individuals like you to help us advocate for meaningful protection of human subjects in research. Donating online with PayPal is quick and easy. Find out more on our Support page


All material on this site © CIRCARE Incorporated (2002- ) or as indicated. Single copies can be downloaded for personal education.   Adobe® Reader ::   ::

Valid HTML 4.01! Valid CSS!